{"id":8476,"date":"2026-08-05T13:43:57","date_gmt":"2026-08-05T08:13:57","guid":{"rendered":"https:\/\/lakshmishree.com\/news\/?p=8476"},"modified":"2026-08-05T13:47:17","modified_gmt":"2026-08-05T08:17:17","slug":"details-of-molbio-diagnostics-ipo","status":"publish","type":"post","link":"https:\/\/lakshmishree.com\/news\/details-of-molbio-diagnostics-ipo\/","title":{"rendered":"Details of Molbio Diagnostics IPO : Lot Size, Check Issue Date, Price"},"content":{"rendered":"\n

Molbio Diagnostics<\/strong> IPO Price: <\/strong>\u20b9768 to \u20b9807 per share<\/p>\n\n\n\n

IPO Dates:<\/strong> 10 Aug to 12 Aug, 2026<\/p>\n\n\n\n

\n
\n
\n
\n
\"Molbio<\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Company Overview<\/strong><\/h2>\n\n\n\n

Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases.<\/p>\n\n\n\n

The company has developed its proprietary ‘Truenat’ platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour<\/p>\n<\/div>\n<\/div>\n\n\n\n

Business Operations<\/h2>\n\n\n\n

Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV.<\/p>\n\n\n\n

The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities.<\/p>\n\n\n\n

Manufacturing & Global Presence<\/h2>\n\n\n\n

The company operates six manufacturing facilities across India and serves customers in over 90 countries.<\/p>\n\n\n\n

Customer Base<\/h2>\n\n\n\n

The company serves government health programs, diagnostic laboratories, hospitals, and international healthcare organizations.<\/p>\n\n\n\n

Workforce<\/h2>\n\n\n\n

As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.<\/p>\n\n\n\n

Market Position<\/h2>\n\n\n\n

Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics.<\/p>\n\n\n\n

Key Strengths<\/h2>\n\n\n\n